SCHEMBL1474956

SCHEMBL1474956

Cc1ccc(-c2cc(C(=O)NCCCn3ccnc3)no2)o1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.74
RAB9A P51151 4/20 0.71
NPC1 O15118 3/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
HTT P42858 1/20 0.71
HIF1A Q16665 1/20 0.71
KDM4E B2RXH2 3/20 0.71
ALDH1A1 P00352 5/20 0.68
GAA P10253 1/20 0.68
GLA P06280 2/20 0.68
HSD17B10 Q99714 2/20 0.68
NFKB1 P19838 1/20 0.67
NFKB2 Q00653 1/20 0.67
RELA Q04206 1/20 0.67
MAPK1 P28482 2/20 0.63
MAPT P10636 2/20 0.57
USP2 O75604 1/20 0.57
HPGD P15428 1/20 0.57
ALOX15 P16050 1/20 0.57
CASP1 P29466 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474189 0.89 LMNA (0.70) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL1178247 0.85 LMNA (1.00) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL1476977 0.85 LMNA (0.65) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL15190177 0.85 LMNA (0.55) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL1178569 0.84 HSD17B10 (0.79) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL1474399 0.84 LMNA (0.86) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL1178443 0.83 RAB9A (0.74) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL1179277 0.83 LMNA (1.00) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL1179553 0.83 KDM4E (1.00) LMNARAB9ANPC1SMN1; SMN2HTT
SCHEMBL1178087 0.83 RAB9A (0.80) LMNARAB9ANPC1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 LMNA 2934/4885RAB9A 2013/4885NPC1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.